Analyst Price Target is $16.67
▲ +1,472.33% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Calidi Biotherapeutics in the last 3 months. The average price target is $16.67, with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 1,472.33% upside from the last price of $1.06.
Current Consensus is
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Calidi Biotherapeutics.
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
Read More